Want to see HK:0348 full AI Analyst Report?
Top Page
China Healthwise Holdings
(0348)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.07
▼(-51.43% Downside)
Action:Upgraded
Date:08/07/26
The score is primarily held back by weak financial performance—ongoing operating losses and, most importantly, negative shareholder equity alongside sizable debt. Technicals also remain soft with price below the 200-day average and negative MACD. Valuation is constrained by a negative P/E (loss-making) and no dividend yield data to offset risk.
Positive Factors
Improving Net Loss
The sharp improvement in net loss indicates some progress in financial performance, even though the company remains unprofitable. If sustained, further loss reduction could improve internal funding capacity and reduce pressure on the balance sheet over the next several reporting periods.
Negative Factors
Revenue Decline
Two consecutive years of declining revenue weaken the foundation for operating leverage and make a durable return to profitability more difficult. Continued contraction can reduce the resources available for investment and leaves the company more dependent on cost control to improve earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Net Loss
The sharp improvement in net loss indicates some progress in financial performance, even though the company remains unprofitable. If sustained, further loss reduction could improve internal funding capacity and reduce pressure on the balance sheet over the next several reporting periods.
Read all positive factors
China Healthwise Holdings (0348) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$64.72M
Dividend YieldN/A
Average Volume (3M)1.81M
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-18.07%
EPS Growth-225.76%
CountryHK
Employees76
SectorHealthcare
Sector Strength45
IndustryLeisure
Share Statistics
EPS (TTM)-0.04
Shares Outstanding924,570,860
10 Day Avg. Volume470,360
30 Day Avg. Volume1,808,180
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)-2.72
Price to Sales (P/S)1.05
P/FCF Ratio35.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Healthwise Holdings Business Overview & Revenue Model
Company Description
China Healthwise Holdings Limited, an investment holding company, engages in the sale of Chinese health products in Hong Kong. It operates through three segments: Chinese Health Products, Money Lending Business, and Investment in Financial Instrum...
China Healthwise Holdings Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.20M | 99.56M | 113.58M | 146.32M | 142.06M | 170.08M |
| Gross Profit | 24.79M | 37.20M | 35.00M | 60.29M | 53.27M | 90.99M |
| EBITDA | -32.47M | -12.34M | -20.07M | -117.45M | -45.80M | -89.97M |
| Net Income | -33.12M | -2.61M | -40.28M | -134.56M | -54.27M | -103.05M |
Balance Sheet | ||||||
| Total Assets | 72.56M | 125.21M | 122.05M | 149.67M | 287.66M | 314.10M |
| Cash, Cash Equivalents and Short-Term Investments | 22.69M | 62.62M | 44.72M | 54.28M | 73.02M | 96.91M |
| Total Debt | 94.61M | 106.13M | 103.74M | 108.90M | 109.90M | 90.86M |
| Total Liabilities | 122.66M | 146.20M | 140.43M | 145.27M | 149.01M | 121.03M |
| Stockholders Equity | -50.10M | -38.49M | -18.38M | 4.40M | 138.65M | 193.06M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.95M | 3.12M | 14.30M | -28.97M | 41.72M |
| Operating Cash Flow | 3.39M | 3.04M | 3.38M | 14.49M | -28.34M | 42.08M |
| Investing Cash Flow | 5.92M | 5.83M | -257.00K | -191.00K | -631.00K | -360.00K |
| Financing Cash Flow | -4.74M | -9.65M | -7.84M | -17.04M | 5.95M | -36.36M |
China Healthwise Holdings Technical Analysis
Negative
0.14
Price Trends
0.07
Negative
0.07
Negative
0.10
Negative
Market Momentum
>-0.01
Positive
44.21
Neutral
38.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0348, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and above the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 38.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0348.
China Healthwise Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$352.42M | 10.76 | 4.28% | 7.86% | -2.78% | -24.77% | |
62 Neutral | HK$469.86M | -145.56 | -0.41% | ― | 3.16% | -101.02% | |
56 Neutral | HK$1.22B | 85.71 | 0.48% | 1.02% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$515.57M | -1.28 | -25.36% | 1.47% | -8.94% | -140.82% | |
44 Neutral | HK$106.89M | -0.67 | -34.98% | 10.09% | -23.52% | -226.85% | |
43 Neutral | HK$64.72M | -1.63 | 82.96% | ― | -18.07% | -225.76% |
* Healthcare Sector Average
HK:0348
China Healthwise Holdings
0.07
-0.08
-53.64%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.22
-0.60
-73.29%
HK:2138
EC Healthcare
0.43
-0.39
-47.56%
HK:3869
Hospital Corporation of China Ltd
3.40
-3.40
-50.00%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-31.52%
HK:0722
UMP Healthcare Holdings Limited
0.42
-0.03
-6.04%
China Healthwise Holdings Corporate Events
China Healthwise Swings to Interim Loss as Revenue Falls
Aug 27, 2026
China Healthwise Holdings reported a sharp deterioration in its unaudited interim results for the six months ended 30 June 2026, with revenue falling to HK$36.5 million from HK$51.1 million a year earlier and gross profit dropping to HK$4.8 millio...
China Healthwise Completes HK$10.8 Million Share Subscription to Fund Operations and Debt Interest
Aug 27, 2026
China Healthwise Holdings Limited has completed a subscription of 154.09 million new shares under its general mandate, representing about 16.7% of its enlarged share capital, at HK$0.07 per share. The transaction, completed on 27 August 2026, intr...
China Healthwise Calls EGM to Approve Share Consolidation Plan
Aug 27, 2026
China Healthwise Holdings Limited has called an extraordinary general meeting in Hong Kong on 18 September 2026 to seek shareholder approval for a proposed share consolidation. The move, conducted under Hong Kong listing rules and overseen via pol...
China Healthwise warns of interim loss on financial instrument and loan impacts
Aug 25, 2026
China Healthwise Holdings has issued an inside information announcement warning that it expects to swing to a loss attributable to shareholders of about HK$28 million to HK$30 million for the six months ended 30 June 2026, compared with a profit o...
China Healthwise Sets August Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
China Healthwise Holdings Limited has scheduled a board meeting for 27 August 2026 to review the unaudited interim results for the six months ended 30 June 2026. The meeting will also consider whether to declare an interim dividend and address oth...
China Healthwise Proposes 5-for-1 Share Consolidation Ahead of 2026 Vote
Aug 13, 2026
China Healthwise Holdings Limited plans to consolidate every five existing shares of HK$0.01 par value into one consolidated share of HK$0.05, reducing its issued share count from 770,480,836 to 154,096,167 while keeping authorised share capital u...
China Healthwise to Raise HK$10.8 Million via Premium Share Subscription
Aug 5, 2026
China Healthwise Holdings has agreed to issue 154,090,000 new shares to an independent merchant subscriber at HK$0.07 per share, representing about 20% of its existing share capital. The subscription price carries a roughly 16.7% premium to the re...
China Healthwise Shareholders Unanimously Approve All AGM Resolutions
Jun 25, 2026
China Healthwise Holdings reported that all resolutions at its 25 June 2026 annual general meeting were approved by shareholders via poll, including receipt of the 2025 audited accounts, re-election of two executive and two independent non-executi...
China Healthwise trims WellCell stake in discloseable share disposal
Jun 8, 2026
China Healthwise Holdings has sold 4,051,200 shares in WellCell, an investment holding company focused on wireless telecommunication network enhancement, ICT integration, software and hardware sales, and fintech services, for about HK$2.27 million...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.